卵巢癌3种蛋白的表达及其与化疗耐药性的关系

THE EXPRESSION OF THREE KINDS OF PROTEINS AND THE RELATIONSHIP WITH CHEMOTHERAPY RESISTANT IN HUMAN OVARIAN CANCER CELL LINES

培养13个卵巢癌细胞系,提取癌细胞蛋白,采用Western印迹法观察NFkB家族蛋白、P53和MDM2的表达,并用四氮唑盐法药敏试验观察与卵巢癌细胞化疗耐药性关系。结果表明:①P65、P50及IKB在胞浆内表达阳性率分别为76.9％、81.8％、84.6％,P65、P50在胞核内表达阳性率分别为15.3％、45.5％,MDM2蛋白表达阳性率为38.5％,P53表达阳性率为46.1％。②2个卵巢癌细胞株P65表达阳性,其IC_(50)显示为明显高值。在MDM2表达阳性的5个卵巢癌细胞株,其中4株IC_(50)显示为高值,P53表达阳性与阴性的卵巢癌细胞中IC_(50)值无明显变化规律。由此说明P65、P50和MDM2与卵巢癌细胞的发生、发展有关;卵巢癌细胞NFkB和MDM2蛋白的表达存在一致性,且两者过度表达与化疗的耐药性有关;NFkB可望成为判断卵巢癌化疗预后新的标志物。

To investigate the relationship between the expression of NFkB family proteins, P53 and MDM2 in ovarian cancer cell lines and chemotherapy resistance of ovarian cell lines, 13 ovarian cancer cell lines were cultured, and then protein was extracted separately from cytoplasm, nuclear or total cells. Using western blotting and MTT chemosensi-tive testing, the relationship between the expression of NFkB family proteins, P53 and MDM2 in ovarian cancer cell lines and chemotherapy resistance of ovarian cell was observed. The results were as follows: ① the expression of positive rate of P65, P50 and IKB in cytoplasm was 76. 9%, 81. 8% and 84. 6%, respectively, and the significant positive expression of P65 and P50 was also found in nuclear, with a rate of 15. 3% , 45. 5% respectively, the expression of positive rate of MDM2 and P53 was 38. 5% and 46.1% respectively in total cells. ②In OV-MZ-5 and OVO-MZ-2774, the expression of P65 was positive and their ICsoreached a significant value. In 4 of 5 ovarian cancer cells, the expression of MDM2 was positive and the IC50also reached a high value. IC 50 value of P53 had no definite trend in expression positive and negative cells. P50, P65 and MDM2 affected the growth and development of ovarian cancer cells. There existed a significant correlation between overexpression of MDN2 and NFkB and the overexpression of NFkB while MDM2 had a relationship with the chemotherapy resistance of ovarian cancer cells, and thus NFkB could be expected to be a new marker in the observation of prognosis.